# Aging-dependent Change in Th17 and Cytokine Response in Multiple Sclerosis

Wen Zhu,<sup>1</sup> Shankar Revu,<sup>2</sup> Chenyi Chen,<sup>1</sup> Megan Dahl,<sup>1</sup> Archana Ramkumar,<sup>1</sup> Conor Kelly,<sup>1</sup> Mandy J McGeachy,<sup>2,3 \*</sup> Zongqi Xia<sup>1 \*</sup>

# \* Share co-senior authorship

# **Corresponding Author:**

Zongqi Xia, MD, PhD
Department of Neurology, University of Pittsburgh
Biomedical Science Tower 3, Suite 10-044, 3501 5<sup>th</sup> Avenue, Pittsburgh, PA 15260
Phone: 412-383-5377; Fax: 412-648-7233; Email: zxia1@post.harvard.edu

<sup>&</sup>lt;sup>1</sup> Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA

<sup>&</sup>lt;sup>2</sup> Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

<sup>&</sup>lt;sup>3</sup> Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA

# **Abstract**

**Background:** Multiple sclerosis (MS) is a chronic autoimmune disease damaging the central nervous system. Diminished inflammatory disease activities (DAs) as people with MS (pwMS) age justified randomized clinical trials assessing disease-modifying therapy (DMT) discontinuation in older pwMS given the concern for risks outweighing benefits.

**Objective**: This study aims to examine the effect of age on DAs and the peripheral production of Myelin Basic Protein (MBP)-driven cytokine response in pwMS.

**Methods:** We included the clinical data of 368 adult pwMS between 2017 and 2021 who enrolled in a clinic-based prospective cohort. From 80 participants, we isolated fresh peripheral blood mononuclear cells (PBMCs) and cultured with 50μg/ml of MBP for 24 hours. We assayed cell culture supernatants for interleukin 17 (IL-17) and interferon gamma (IFN-γ) using Enzyme-Linked Immunosorbent Assay and a subset of the supernatant samples using a commercial human cytokine/chemokine array. We examined the associations between age and annualized relapse rate (ARR) as well as between age and MBP-stimulated cytokine production (by cultured PBMC) using covariate-adjusted linear regressions. We performed mediation analyses to determine the extent to which MBP-driven cytokine responses drive the association between age and ARR.

**Results:** Among the 386 pwMS (mean age 53.1±12.6 years, 79.9% women, 92.1% non-Hispanic White), ARR declined with age (β=-0.003, p<0.001). Among the 80 pwMS whose cultured PBMCs underwent ex vivo MBP stimulation, IL-17 production declined with age in women (β=-0.27, p=0.04) but not men (β=-0.1, p=0.73). MBP-driven IL-17 response partially mediated the association between older age and lower ARR (24.7% in women, 15.3% in men). In exploratory analysis, older pwMS (≥50 years) had marginally lower (IL-4, MCP-2, MCP-3, PDGF-AA, PDGF-AB/BB) and higher (Fractalkine,

MDC) concentrations of several cytokines than younger pwMS (<50 years). Some cytokines (MCP-2, MDC) mediate while others negate the effect of age on ARR.

**Conclusion:** This study suggests some of the potential biological mechanisms driving agingdependent decline in MS inflammatory DA that warrant further investigation.

# **Key Words:**

Multiple sclerosis, myelin basic protein, Th17, aging, relapse, inflammatory disease activity

# Introduction

Multiple sclerosis (MS) is a chronic autoimmune disease that causes inflammatory demyelination and progressive neurodegeneration in the central nervous system (CNS). Aging correlates with MS disease progression.[1,2] In people with MS (pwMS), 45 years of age seem to mark an inflection point when the relapse rate declines while the rate of disability accrual increases.[3] Both the inflammatory disease activity and the potential for a full recovery after a relapse diminish with increasing age,[4] potentially due to the diminished CNS "reserve" and the decreasing capacity to restore function with aging.[2] These considerations have motivated randomized clinical trials testing the safety of immune modulating therapy discontinuation in older pwMS with stable inflammatory disease activity given the concern for risks outweighing benefits.[5,6]

Interleukin-17 (IL-17) is a cytokine that promotes blood-brain barrier permeability, proinflammatory signaling in astrocytes, neuronal hyperexcitability, and depletion of oligodendrocyte
precursors necessary for repairing the damaged CNS.[7,8] Consistent with its role in driving
autoimmunity, IL-17 enhances B cell activation and autoantibody production in models of MS,[9,10]
while increased IL-17 expression is found at sites of acute and chronic inflammation in pwMS.[11]
Myelin-reactive CD4+ T helper (Th) cells, particularly Th17 cells that produce IL-17, are crucial in MS
pathogenesis. Depletion of Th17 cells in a murine model of experimental autoimmune demyelination
protects against the induction of MS-like pathology and phenotype.[12] Th17 cells are more abundant
in the blood and cerebrospinal fluid of pwMS than healthy controls, and they further expand during
active MS relapses.[13–16] Th17 cells encompass subpopulations that differentially produce IL-17
alone or in combination with other proinflammatory cytokines such as interferon-gamma (IFNy) with
the latter "Multi-functional" Th17 cells considered as more pathogenic. Overall Th17 cell frequency is
higher in both people with relapsing-remitting MS (RRMS) and secondary-progressive MS (SPMS)

than in healthy controls, while double-positive IL-17<sup>+</sup> IFNγ<sup>+</sup> Th17 cells are higher in the inflammation-predominant RRMS than the neurodegeneration-predominant SPMS.[17]

Immunosenescence and inflammaging potentially explain the aging-associated decline in MS disease activity. Immunosenescence describes dysregulated adaptive and innate immune responses that increase the risk of infection and malignancy as people age, while inflammaging refers to the low-grade chronic inflammation throughout the aging process that produces a broad range of tissue damages and chronic conditions. The former may contribute to the decline in acute inflammatory demyelination events while the latter may contribute to the disability accrual and disease progression with aging.[18] Among the cells crucial in MS pathogenesis and progression, Th17 cells also play a significant role in mediating inflammaging.[19,20] In a study of 122 pwMS, aging and Th17-dominant immune response profile (a higher Th17/Treg ratio after positively weighting IL-6 and IL-17 for Th17 and negatively weighting IL-10 for Treg) were independently associated with MS disability.[21]

Few studies to date have examined immune drivers of aging-related decline in MS relapse rate, particularly the role of Th17 cells. Myelin basic protein (MBP) is an abundant protein in the CNS myelin and a putative MS auto-antigen, and cytokines released from MBP-stimulated peripheral immune cells isolated from pwMS represent an experimental paradigm to investigate MS-relevant mechanisms.[22–30] In this study, we examined the relationships between age and relapse in pwMS and whether MBP-induced Th17/IL-17 and other cytokine responses mediate these associations.

### **Methods**

#### Study Design, Participants and Samples

This cross-sectional study included 368 participants (primary cohort) who enrolled in a clinic-based prospective cohort study (Prospective Investigation of Multiple Sclerosis in the Three Rivers

Region, PROMOTE; Pittsburgh, PA) during 2017-2021 (Figure 1).[31–42] The cohort enrollment criteria included adults 18 years or older with a neurologist-confirmed diagnosis of MS according to the 2017 McDonald criteria. Given the clinical outcome of interest is relapse event indicative of inflammatory disease activity, we included pwMS of relapsing remitting (RRMS) and secondary progressive (SPMS) type and excluded primary progressive type (PPMS), which is not characterized by relapse events. To collect blood sample for MBP-stimulation assays, we randomly selected a subset of 80 participants (Th17 cohort) to achieve a 1:2 men to women ratio and relatively balanced distribution across age groups from 25 to 75 years old. Participants donated venous blood samples for research during routine clinical appointments. The blood samples were immediately processed for the downstream experiments.

# Ethics Approval

The institutional review board of the University of Pittsburgh (STUDY19080007) approved the study protocols. All participants provided written informed consent.

# Age as Exposure and Other Covariates

We collected demographic and clinical data, including age (at the time of relapse history annotation [primary cohort] or blood sample collection [Th17 cohort]), sex (designated at birth: men versus women), race/ethnicity (non-Hispanic White versus otherwise given the relatively low proportion of individuals who are not non-Hispanic White in the clinic population), disease subtype (RRMS versus SPMS), disease duration and use of disease modifying therapy [DMT] (high-efficacy versus standard-efficacy versus no DMT at the time of relapse annotation [primary cohort] or blood sample collection [Th17 cohort]) through review of the electronic health records (EHR). Disease

duration was defined as the time interval between MS diagnosis and the time of relapse history annotation (primary cohort) or blood sample collection (Th17 cohort). For DMT, we categorized natalizumab, ocrelizumab, and rituximab as higher-efficacy, while dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta and teriflunomide as standard-efficacy.

### Relapse Rate as the Clinical Outcome

We annotated relapse events through EHR review. A relapse event could be a clinical and/or radiologic relapse. Clinical relapses are either new or recurrent neurological symptoms (relevant to MS) lasting persistently for 24 hours or longer without fever or infection. Radiological relapses are new T1-enhancing lesion(s) and/or new or enlarging T2 fluid attenuated inversion recovery (FLAIR) hyperintense lesion(s) based on clinical radiology reports of routine brain, orbit, or spinal cord magnetic resonance imaging (MRI) studies. For the primary cohort, we calculated the annualized relapse rate (ARR) in the two years preceding the annotation of relapse history. For the Th17 cohort, we calculated the ARR encompassing the two years preceding and the two years after the blood sample collection. ARR is a commonly used MS relapse outcome.

### MBP Stimulation Assay

From freshly collected whole blood, we isolated peripheral blood mononuclear cells (PBMCs) by Ficoll-plague (Sigma-Aldrich) density gradient centrifugation (400x g) for 30 min at room temperature with no brake. PBMCs were collected, washed twice with PBS at (200x g) for 15 min at 4°C, and then cultured at a density of 2x10<sup>6</sup> cells per well in 24-well plate with 50 μg/mL of human MBP antigen (catalog #M0689, Sigma Aldrich) for 24 hours. Our prior unpublished preliminary

experiments showed more consistent findings using 24 hours of culture than longer periods of incubation.

### MBP-driven Cytokines

We collected supernatants of cultured PBMCs after 24-hour ex vivo MBP stimulation and performed enzyme-linked immunosorbent assay (ELISA) using the Ready-SET-Go kit for human IL-17 (catalog #88-7176-88) and IFN-γ (catalog #88-7316-88) (eBioscience) according to the manufacturer's instructions. We performed ELISA assays of each supernatant sample in duplicates and calculated the mean concentrations of the duplicates. In addition, we analyzed a subset of supernatant samples using the Luminex xMAP platform human cytokine/chemokine array (Eve Technologies, Canada).

## Statistical Analysis

To select the covariates in downstream analysis, we first examined the associations between potentially relevant clinical or demographic variables (sex, race/ethnicity, disease subtype and DMT efficacy) and MS relapse outcome (*i.e.*, ARR) using univariate linear regressions. We did not include disease duration as a covariate given its high correlation with the exposure of interest (*i.e.*, age). We then assessed the associations between age and ARR, age and (concentration of) MBP-stimulated cytokines, and MBP-stimulated cytokines and ARR using multi-variate linear regressions accounting for potential confounders deemed significant in the univariate analyses. We assessed the proportion of the association between age and ARR explained by the MBP-driven cytokine responses (Th17/IL-17 and other cytokines) using a mediation test. The total effect of the exposure (*i.e.*, age) on the outcome (*i.e.*, ARR) encompasses both direct effect (of the exposure on the outcome) and indirect

effect mediated through one or more intermediaries (*e.g.*, cytokine).[43] A two-tailed p-value <0.05 was deemed statistically significant. We performed all analyses using R, version 4.0.2.

# **Results**

# Inverse association between age and relapse rate in pwMS

We included the clinical data of 368 adult pwMS (mean age 53.1±12.6 years, 79.9% women, 92.1% non-Hispanic White) who enrolled in the long-term PROMOTE cohort between 2017 and 2021 (Table 1). Among these 368 participants that constitute the *primary cohort* of this study, there was a statistically significant inverse association between age and ARR, which remained significant (beta = -0.007, 95%CI [-0.009, -0.005], p<0.001) after accounting for covariates selected by the univariate analyses (*i.e.*, sex and race/ethnicity) (Table 2). In a randomly selected subset of 80 participants that constitute the *Th17 cohort* who donated PBMCs for the ex vivo MBP-stimulation assays, the inverse association between age and ARR remained significant after covariate adjustment (beta = -0.016, 95%CI [-0.024, -0.005], p=0.002). To reduce over-correction, we did not include disease duration as a covariate in the analyses because of its strong correlation with age.

### Inverse association between age and MBP-driven IL-17 responses in women with MS

To assess the association between age and MBP-driven Th17/IL-17 response, we considered age as either a continuous variable or a binary variable using ≥50 versus <50 years as the threshold. The binary age threshold is based on prior clinical studies examining the age-related decline in MS relapse rate.[6] In the full Th17 cohort, age was not significantly associated with MBP-driven IL-17 expression (Figure 2A and D). Interestingly, there was a significant inverse association between age and MBP-driven IL-17 response in women (age as a continuous variable: beta = -0.268, 95%CI [-

0.519, -0.018], p=0.04; age as a binary variable: p=0.031) but not in men (Fig 2B and 2E versus Fig 2C and 2F). When assessing the association between the MBP-driven IL-17 response and ARR, we found significantly positive correlations in women (beta = 0.007, 95%CI [0.002, 0.012], p=0.01) but not in men (Figure 3). With the caveat that there were fewer men than women analyzed (reflecting the typical ratio of men versus women in MS), these findings support further investigation of the sex differences in MBP-driven peripheral immune response in larger cohorts.

To assess the extent to which MBP-driven IL-17 response explains the inverse association between age and ARR, we performed mediation analysis (Table 3). We estimated that MBP-driven IL-17 response mediated 24.6% of the effect of older age on lower ARR in women versus 15.3% in men.

IFN-γ is produced by Th1 cells and Th17 cells. As controls, we similarly measured MBP-driven IFN-γ responses and found no statistically significant association between age and MBP-driven IFN-γ response or MBP-driven IFN-γ response and ARR in the Th17 cohort (full, women, men) (Supplementary Figure 1).

### Age and other MBP-driven cytokine responses

Given that other cytokines beyond IL-17 might also change with aging in pwMS, we performed exploratory analysis of additional MBP-driven cytokine responses in 28 samples from the Th17 cohort (women=20, men=8) using the Luminex xMAP platform human cytokine/chemokine array. We did not stratify the samples by sex in these exploratry analyses due to the modest sample size. We assayed 57 MBP-driven cytokine responses across the 28 samples and organized the findings in order of ascending age (Figure 4A). Seven cytokines showed significant associations with age when evaluating age as either a continuous or a binary variable (Figure 4B, Figure 5, Supplementary Table

1). In this pilot data set, age as a continuous variable was positively associated with Fractalkine (beta = 0.238, 95%CI [0.000, 0.478], p=0.051) and MDC (beta = 9.649, 95%CI [4.808, 14.489], p<0.001) but inversely associated with IL-4 (beta = -0.004, 95%CI [-0.009, -3.943], p=0.048), MCP-2 (beta = -12.350, 95%CI [-22.406, -2.295], p=0.018), MCP-3 (beta = -24.218, 95%CI [-41.476, -6.961], p=0.008), PDGF-AA (beta = -0.851, 95%CI [-1.504, -0.197], p=0.013), and PDGF-AB/BB (beta = -7.154, 95%CI [-11.232, -3.075], p=0.001) (Figure 5). There were similarly significant associations when using age as a binary variable. We consider these associations as *marginally significant* since none survived multiple testing correction for false discovery rate (Supplementary Table 1). We also explored the extent to which these seven marginally significant MBP-driven cytokine responses mediated the association between older age and lower ARR. Two cytokines mediated the effect of age on ARR in similar proportions: MCP-2 (4.15%), MDC (4.53%). Interestingly, other cytokines (Fractalkine, IL-4, MCP-3, PDGF-AA, and PDGF-AB/BB) might negate the effect of age on ARR with the proportion of cytokine-negated effect ranging from 0.75% (PDGF-AB/BB) to 16.98% (IL-4) (see details in Supplementary Table 2).

### **Discussion**

In this clinic-based cohort study, we confirmed the declining relapse rate (*i.e.*, ARR) with increasing age in pwMS. As a potential mechanism to explain this important clinical observation that has been the basis for randomized clinical trials of DMT discontinuation in older pwMS, MBP-driven IL-17 response, but not IFN-γ response, declined with increasing age in women but not men with MS. MBP-driven IL-17 response partially mediated the effect of older age on lower ARR to a greater extent in women (24.7%) than men (15.3%). In an exploratory analysis of other MBP-driven cytokines, older pwMS (50 years and older) exhibited lower concentrations of IL-4, MCP-2, MCP-3,

PDGF-AA, PDGF-AB/BB while higher concentrations Fractalkine and MDC than younger pwMS (below 50 years of age).

This study has several strengths. First, this is the first study to our knowledge that examined the potential peripheral immune drivers of the declining inflammatory disease activity with aging in pwMS using the practical experimental paradigm of patient derived PBMCs stimulated ex vivo with MBP, an abundant CNS myelin protein and a putative autoantigen. This approach enables the investigation of potential changes in MS-relevant autoimmune inflammatory response and associated biomarkers of clinical relevance in older pwMS. Second, we performed mediation analyses to estimate the extent to which a given MBP-driven cytokine response mediates the aging-related decline in inflammatory disease activity in pwMS, enabling comparison between men and women as well as across different cytokines. Third, this study examined the sex difference in potential immune mechanisms underlying aging in MS. Although sex difference in MS susceptibility is well recognized, little is known regarding the sex difference in peripheral immune responses in older pwMS. We found that the extent to which MBP-driven Th17 response mediated aging-related decline in MS inflammatory disease activity (i.e., relapse rate) was greater in women than men. Finally, we explored a broader group of MBP-driven cytokine responses beyond Th17/IL-17 that may additionally mediate (or negative) disease activity in aging pwMS. These findings collectively generate hypotheses for future studies of the mechanisms of aging in MS and age- and sex-specific biomarkers of MS disease progression.

Peripheral immune drivers of MS inflammatory disease activity are postulated to differ by sex, which may support the clinical observation that MS diagnosis is more common in women than men while men with MS is prone to develop progressive disease and disability progression than women.[44] The existing literature indicates at least two concurrent pathogenic processes across the

MS disease stages that are also potentially relevant to aging in MS.[45,46] First, acute inflammatory demyelination and relapse events are underscored by the migration of peripheral CD8<sup>+</sup> and CD4<sup>+</sup> T cells and CD20<sup>+</sup> B cells into the CNS. Second, progressive neurodegeneration and disability accrual are driven by microglia and macrophage activation, oxidative injury, and mitochondrial damage that can begin concurrently in the early stages of the disease and involve the gradual accumulation of late-differentiated T and B cells in the meninges and periventricular spaces. There are likely sex differences in the development of these two processes in MS. A single-cell transcriptomic analysis examining the effects of sex and age on the peripheral immune cell landscape in the general human population reported higher percentage of plasma cells and over-representation of gene expression pathways relevant to the adaptive immune function (B and T cell activation) in women versus higher percentage of NK cells and higher expression of pro-inflammatory genes in men. Importantly, aging further amplified the observed sex differences.[47] Dysregulation of T-cell subtypes occurs with normal aging in the broader population, manifesting paradoxically as an aging-dependent increase in Th17/Treg ratio at baseline but reduced Th17/Treg ratio after stimulation (by phytohaemagglutinin, a potent stimulator of IL-17 response in PBMCs though not necessarily specific for MS).[19] Menopause in women is a potential aging-related inflection point (around 40-50 years of age) in immune alteration, accompanied by an increase in Th17/Treg ratio.[48] Given the current understanding that adaptive immunity (e.g., B and T cell activation) is generally more robust in women than men while aging-dependent Th17/Treg dysregulation coincides with the perimenopausal period (a key milestone in female aging) and exposure to non-MS specific stimulant of IL-17 paradoxically reduces the aging-dependent Th17/Treg ratio, it is conceivable that the agingdependent decline in MS relapse rate may be driven by the diminishing MBP-driven IL-17 responses to a greater extent in women than men, as reported in this study.

The main study limitations pertain to the sex imbalance in sample size, low racial and ethnic diversity, a single center cohort and cross-sectional data set. Given that the study population drew from a pragmatic real-world clinic-based cohort of pwMS in the Western Pennsylvania region of the United States, we are limited by the available research participants who are over-represented by women and non-Hispanic White individuals, largely reflecting the broader clinic population. Future validation studies that include a larger sample size, greater proportion of men and historically under-represented racial and ethnic groups, external samples and data sources as well as a longitudinal study design would further enhance the robustness of our findings.

# Conclusion

This study highlights the potentially important role of MBP-driven Th17/IL-17 response and additional peripheral immune cytokine mediators in aging-dependent decline in MS inflammatory disease activity, particular in women with MS.

# **Acknowledgment**

We appreciate the contribution of research participants and clinicians at the UPMC MS Center.

# **Declaration of Conflict of Interest**

The authors report no relevant conflict of interest.

# **Data Sharing**

Code for analysis and figures is available at <a href="https://github.com/xialab2016/AgeandTh17.git">https://github.com/xialab2016/AgeandTh17.git</a>. Deidentified data are available upon request to the corresponding author and with permission from the participating institutions.

### Reference

- 1. Capasso N, Virgilio E, Covelli A, Giovannini B, Foschi M, Montini F, Nasello M, Nilo A, Prestipino E, Schirò G, et al.: **Aging in multiple sclerosis: from childhood to old age, etiopathogenesis, and unmet needs: a narrative review**. *Front Neurol* 2023, **14**:1207617.
- 2. Zeydan B, Kantarci OH: **Impact of Age on Multiple Sclerosis Disease Activity and Progression**. *Curr Neurol Neurosci* 2020, **20**:24.
- 3. Wyl V, Décard BF, Benkert P, Lorscheider J, Hänni P, Lienert C, Kuhle J, Derfuss T, Kappos L, Yaldizli Ö: Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment. *Eur J Neurol* 2020, **27**:1066–1075.
- 4. Conway BL, Zeydan B, Uygunoğlu U, Novotna M, Siva A, Pittock SJ, Atkinson EJ, Rodriguez M, Kantarci OH: **Age is a critical determinant in recovery from multiple sclerosis relapses**. *Mult Scler J* 2018, **25**:1754–1763.
- 5. Corboy JR, Fox RJ, Kister I, Cutter GR, Morgan CJ, Seale R, Engebretson E, Gustafson T, Miller AE, investigators D, et al.: Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. *Lancet Neurol* 2023, 22:568–577.
- 6. Zhu W, Xia Z: **Treatment discontinuation in older people with multiple sclerosis**. *Curr Opin Neurol* 2024, doi:10.1097/wco.00000000001272.
- 7. Majumder S, McGeachy MJ: **IL-17 in the Pathogenesis of Disease: Good Intentions Gone Awry**. *Annu Rev Immunol* 2021, **39**:1–20.
- 8. Milovanovic J, Arsenijevic A, Stojanovic B, Kanjevac T, Arsenijevic D, Radosavljevic G, Milovanovic M, Arsenijevic N: **Interleukin-17 in Chronic Inflammatory Neurological Diseases**. *Front Immunol* 2020, **11**:947.
- 9. Mitsdoerffer M, Lee Y, Jäger A, Kim H-J, Korn T, Kolls JK, Cantor H, Bettelli E, Kuchroo VK: **Proinflammatory T helper type 17 cells are effective B-cell helpers**. *Proc Natl Acad Sci* 2010, **107**:14292–14297.
- 10. Majumder S, Amatya N, Revu S, Jawale CV, Wu D, Rittenhouse N, Menk A, Kupul S, Du F, Raphael I, et al.: **IL-17 metabolically reprograms activated fibroblastic reticular cells for proliferation and survival**. *Nat Immunol* 2019, **20**:534–545.

- 11. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L: Interleukin-17 Production in Central Nervous System-Infiltrating T Cells and Glial Cells Is Associated with Active Disease in Multiple Sclerosis. *Am J Pathol* 2008, 172:146–155.
- 12. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ: **IL-23 drives a pathogenic T cell population that induces autoimmune inflammation**. *J Exp Med* 2005, **201**:233–240.
- 13. Christensen JR, Börnsen L, Ratzer R, Piehl F, Khademi M, Olsson T, Sørensen PS, Sellebjerg F: Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17-and Activated B-Cells and Correlates with Progression. *PLoS ONE* 2013, 8:e57820.
- 14. Fransson ME, Liljenfeldt LSE, Fagius J, Tötterman TH, Loskog ASI: **The T-cell pool is anergized in patients with multiple sclerosis in remission**. *Immunology* 2009, **126**:92–101.
- 15. Hansen RH, Talbot J, Chow HH, Hansen MB, Buhelt S, Herich S, Schwab N, Hellem MNN, Nielsen JE, Sellebjerg F, et al.: Increased Intrathecal Activity of Follicular Helper T Cells in Patients With Relapsing-Remitting Multiple Sclerosis. *Neurol: Neuroimmunol Neuroinflammation* 2022, **9**:e200009.
- 16. Li Y, Wang H, Long Y, Lu Z, Hu X: Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. *J Neuroimmunol* 2011, **234**:155–160.
- 17. Kalra S, Lowndes C, Durant L, Strange R, Al-Araji A, Hawkins CP, Curnow SJ: **Th17 cells increase in RRMS as well as in SPMS, whereas various other phenotypes of Th17 increase in RRMS only**. *Multiple Scler J Exp Transl Clin* 2020, **6**:2055217319899695.
- 18. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A: **Inflammaging: a new immune-metabolic viewpoint for age-related diseases**. *Nat Rev Endocrinol* 2018, **14**:576–590.
- 19. Schmitt V, Rink L, Uciechowski P: **The Th17/Treg balance is disturbed during aging**. *Exp Gerontol* 2013, **48**:1379–1386.
- 20. Merino KM, Jazwinski SM, Rout N: **Th17-type immunity and inflammation of aging**. *Aging (Albany NY)* 2021, **13**:13378–13379.
- 21. Flauzino T, Simão ANC, Pereira WL de CJ, Alfieri DF, Oliveira SR, Kallaur AP, Lozovoy MAB, Kaimen-Maciel DR, Maes M, Reiche EMV: **Disability in multiple sclerosis is associated with age and inflammatory, metabolic and oxidative/nitrosative stress biomarkers: results of multivariate and machine learning procedures**. *Metab Brain Dis* 2019, **34**:1401–1413.
- 22. Olsson T, Sun J, Hillert J, Höjeberg B, Ekre H, Andersson G, Olerup O, Link H: **Increased numbers of T cells recognizing multiple myelin basic protein epitopes in multiple sclerosis**. *Eur J Immunol* 1992, **22**:1083–1087.

- 23. Hedegaard CJ, Krakauer M, Bendtzen K, Lund H, Sellebjerg F, Nielsen CH: **T helper cell type 1** (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. *Immunology* 2008, **125**:161–169.
- 24. Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F: **T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-**β. *Ann Neurol* 2009, **65**:499–509.
- 25. Huber AK, Wang L, Han P, Zhang X, Ekholm S, Srinivasan A, Irani DN, Segal BM: **Dysregulation of the IL-23/IL-17 axis and myeloid factors in secondary progressive MS**. *Neurology* 2014, **83**:1500–1507.
- 26. Monreal MTM, Hansen BE, Iversen PF, Enevold C, Ødum N, Sellebjerg F, Højrup P, Essen MR von, Nielsen CH: Citrullination of myelin basic protein induces a Th17-cell response in healthy individuals and enhances the presentation of MBP85-99 in patients with multiple sclerosis. *J Autoimmun* 2023, **139**:103092.
- 27. Martinsen V, Kursula P: **Multiple sclerosis and myelin basic protein: insights into protein disorder and disease**. *Amino Acids* 2022, **54**:99–109.
- 28. Revu SK, Yang W, Rajasundaram D, Brady A, Majumder S, Gaffen SL, Hawse W, Xia Z, McGeachy MJ: **Human IL-17A protein production is controlled through a PIP5K1α-dependent translational checkpoint**. *Sci Signal* 2023, **16**:eabo6555.
- 29. Hedegaard CJ, Enevold C, Sellebjerg F, Bendtzen K, Nielsen CH: **Variation in NOD2 Augments Th2- and Th17 Responses to Myelin Basic Protein in Multiple Sclerosis**. *PLoS ONE* 2011, **6**:e20253.
- 30. Wing AC, Hygino J, Ferreira TB, Kasahara TM, Barros PO, Sacramento PM, Andrade RM, Camargo S, Rueda F, Alves-Leon SV, et al.: Interleukin-17- and interleukin-22-secreting myelin-specific CD4+ T cells resistant to corticoids are related with active brain lesions in multiple sclerosis patients. *Immunology* 2016, 147:212–220.
- 31. Santini T, Chen C, Zhu W, Liou J-J, Walker E, Venkatesh S, Farhat N, Sajewski A, Alkhateeb S, Saranathan M, et al.: **Hippocampal subfields and thalamic nuclei associations with clinical outcomes in multiple sclerosis: an ultrahigh field MRI study**. *Mult Scler Relat Disord* 2024, doi:10.1016/j.msard.2024.105520.
- 32. Levin SN, Riley CS, Dhand A, White CC, Venkatesh S, Boehm B, Nassif C, Socia L, Onomichi K, Leavitt VM, et al.: **Association of social network structure and physical function in patients with multiple sclerosis**. *Neurology* 2020, **95**:e1565–e1574.
- 33. Levin SN, Venkatesh S, Nelson KE, Li Y, Aguerre I, Zhu W, Masown K, Rimmer KT, Diaconu CI, Onomichi KB, et al.: **Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases**. *Ann Clin Transl Neur* 2021, **8**:918–928.

- 34. Mani A, Santini T, Puppala R, Dahl M, Venkatesh S, Walker E, DeHaven M, Isitan C, Ibrahim TS, Wang L, et al.: **Applying Deep Learning to Accelerated Clinical Brain Magnetic Resonance Imaging for Multiple Sclerosis**. *Front Neurol* 2021, **12**:685276.
- 35. Epstein S, Xia Z, Lee AJ, Dahl M, Edwards K, Levit E, Longbrake EE, Perrone C, Kavak K, Weinstock-Guttman B, et al.: **Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data**. *Mult Scler Relat Disord* 2022, **57**:103433.
- 36. Levit E, Cohen I, Dahl M, Edwards K, Weinstock-Guttman B, Ishikawa T, Kavak K, Leavitt V, Nelson K, Onomichi K, et al.: **Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic**. *Mult Scler Relat Disord* 2022, **58**:103482.
- 37. Kever A, Walker ELS, Riley CS, Heyman RA, Xia Z, Leavitt VM: **Association of personality traits with physical function, cognition, and mood in multiple sclerosis**. *Mult Scler Relat Disord* 2022, **59**:103648.
- 38. Chikersal P, Venkatesh S, Masown K, Walker E, Quraishi D, Dey A, Goel M, Xia Z: **Predicting Multiple Sclerosis Outcomes During the COVID-19 Stay-at-home Period: Observational Study Using Passively Sensed Behaviors and Digital Phenotyping**. *JMIR Ment Heal* 2022, **9**:e38495.
- 39. Boorgu DSSK, Venkatesh S, Lakhani CM, Walker E, Aguerre IM, Riley C, Patel CJ, Jager PLD, Xia Z: **The impact of socioeconomic status on subsequent neurological outcomes in multiple sclerosis**. *Mult Scler Relat Disord* 2022, **65**:103994.
- 40. Jakimovski D, Kavak KS, Longbrake EE, Levit E, Perrone CM, Bar-Or A, Benedict RH, Riley CS, Jager PLD, Venkatesh S, et al.: Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic. *Mult Scler Relat Disord* 2022, **68**:104235.
- 41. Zhu W, Chen C, Zhang L, Hoyt T, Walker E, Venkatesh S, Zhang F, Qureshi F, Foley JF, Xia Z: **Association between serum multi-protein biomarker profile and real-world disability in multiple sclerosis**. *Brain Commun* 2023, **6**:fcad300.
- 42. Riley C, Venkatesh S, Dhand A, Doshi N, Kavak K, Levit E, Perrone C, Weinstock-Guttman B, Longbrake E, Jager PD, et al.: Impact of the COVID-19 Pandemic on the Personal Networks and Neurological Outcomes of People With Multiple Sclerosis: Cross-Sectional and Longitudinal Case-Control Study. *JMIR Public Heal Surveill* 2024, **10**:e45429.
- 43. Boekel L, Atiqi S, Leeuw M, Hooijberg F, Besten YR, Wartena R, Steenhuis M, Vogelzang E, Webers C, Boonen A, et al.: **Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands**. *The Lancet Rheumatol* 2023, doi:10.1016/s2665-9913(23)00127-3.

- 44. Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RH, Zipp F, Weinstock-Guttman B: **Multiple sclerosis**. *Lancet* 2024, **403**:183–202.
- 45. Thakolwiboon S, Mills EA, Yang J, Doty J, Belkin MI, Cho T, Schultz C, Mao-Draayer Y: Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration. *Front Aging* 2023, **4**:1234572.
- 46. Lassmann H: Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis. *Front Immunol* 2019, **9**:3116.
- 47. Huang Z, Chen B, Liu X, Li H, Xie L, Gao Y, Duan R, Li Z, Zhang J, Zheng Y, et al.: **Effects of sex and aging on the immune cell landscape as assessed by single-cell transcriptomic analysis**. *Proc Natl Acad Sci* 2021, **118**:e2023216118.
- 48. Han A, Kim JY, Kwak-Kim J, Lee SK: **Menopause is an inflection point of age-related immune changes in women**. *J Reprod Immunol* 2021, **146**:103346.

**Table 1. Cohort characteristics** 

|                                     | Primary Cohort   |                    |                 | Th17 Cohort      |                   |                 |  |
|-------------------------------------|------------------|--------------------|-----------------|------------------|-------------------|-----------------|--|
|                                     | All<br>(n = 368) | Women<br>(n = 294) | Men<br>(n = 74) | All<br>(n = 80)  | Women<br>(n = 56) | Men<br>(n = 24) |  |
| Age<br>(years, mean ± SD)           | 53.1 (12.6)      | 53.2 (12.2)        | 52.7 (14.1)     | 47.15 (13.3)     | 47.3 (13.5)       | 46.8 (13.3)     |  |
| Race/Ethnicity (% of cohort)        |                  |                    |                 |                  |                   |                 |  |
| Non-Hispanic White                  | 337 (92.1)       | 268 (91.8)         | 69 (93.2)       | 74 (86.0)        | 48 (85.7)         | 21 (87.5)       |  |
| Other                               | 31 (7.9)         | 26 (8.2)           | 5 (6.8)         | 12 (14.0)        | 8 (14.3)          | 3 (12.5)        |  |
| Disease Duration (years, mean ± SD) | 16.2 (10.0)      | 16.3 (9.6)         | 15.5 (11.4)     | 13.34<br>(10.15) | 14.3 (10.6)       | 12.5 (9.6)      |  |
| Disease Subtype (n, % of cohort)    |                  |                    |                 |                  |                   |                 |  |
| RRMS                                | 354 (96.2)       | 285 (96.9)         | 65 (87.8)       | 78 (97.5)        | 56 (100.0)        | 22 (91.7)       |  |
| SPMS                                | 18 (4.9)         | 9 (3.1)            | 9 (12.2)        | 2 (2.5)          | 0 (0.0)           | 2 (8.3)         |  |
| DMT Treatment (n, % of cohort)      |                  |                    |                 |                  |                   |                 |  |
| No DMT                              | 127 (29.1)       | 103 (35.0)         | 24 (32.4)       | 16 (20.0)        | 13 (23.2)         | 3 (12.5)        |  |
| Standard-efficacy DMT               | 79 (21.5)        | 65 (22.1)          | 14 (18.9)       | 23 (28.7)        | 20 (35.7)         | 3 (12.5)        |  |
| High-efficacy DMT                   | 162 (44.0)       | 126 (42.9)         | 36 (48.7)       | 41 (51.2)        | 23 (41.1)         | 18 (75.0)       |  |

## Abbreviations:

SD, standard deviation; RRMS, relapse-remitting MS; SPMS, secondary progressive MS; DMT, disease-modifying therapy.

Table 2. Age is inversely associated with annualized relapse rate (ARR) in pwMS

|  |                  | Primary Cohort<br>(n = 368)         |         | Th17 Cohort<br>(n = 80)             |         |
|--|------------------|-------------------------------------|---------|-------------------------------------|---------|
|  |                  | Coefficient <sup>4</sup><br>(95%CI) | p-value | Coefficient <sup>4</sup><br>(95%CI) | p-value |
| Unadjusted Linear<br>Regression <sup>1</sup> |                  |                                     |         |                                     |         |
|  | ARR <sup>3</sup> | -0.003<br>(-0.004, -0.002)          | < 0.001 | -0.016<br>(-0.017, -0.006)          | < 0.001 |
| Adjusted Linear<br>Regression <sup>2</sup>   |                  |                                     |         |                                     |         |
|  | ARR <sup>3</sup> | -0.007<br>(-0.009, -0.005)          | < 0.001 | -0.016<br>(-0.024, -0.005)          | 0.002   |

#### Note:

- 1. Unadjusted linear regression: ARR ~ age.
- 2. Adjusted linear regression: ARR ~ age + sex + race/ethnicity.
- 3. Annualized relapse rate (ARR) definition: In the primary cohort, ARR was calculated in the 2 years preceding the relapse history annotation date. In the Th17 cohort, ARR was calculated within ± 2 years of sample collection.
- 4. Coefficient for age.

Abbreviations: CI, confidence interval

Table 3. MBP-driven IL-17 response as a mediator of the inverse association between age and MS inflammatory disease activity.

|                              | All (n=80)               |         |  |
|------------------------------|--------------------------|---------|--|
|                              | Coefficient (95%CI)      | p-value |  |
| Total effect 1               | -0.141(-0.255, -0.048)   | 0.004   |  |
| Direct effect <sup>2</sup>   | -0.138 (-0.250, -0.041)  | 0.012   |  |
| Indirect effect <sup>3</sup> | -0.003 (-0.038, -0.010)  | 0.652   |  |
|                              | Women (n=56)             |         |  |
|                              | Coefficient              | p-value |  |
| Total effect 1               | -0.150 (-0.262, -0.035)  | 0.012   |  |
| Direct effect <sup>2</sup>   | -0.113 (-0.230, -0.0003) | 0.048   |  |
| Indirect effect <sup>3</sup> | -0.037(-0.105, -0.009)   | 0.128   |  |
|                              | Men (n=24)               |         |  |
|                              | Coefficient              | p-value |  |
| Total effect 1               | -0.111 (-0.330, 0.095)   | 0.3     |  |
| Direct effect <sup>2</sup>   | -0.094 (-0.311, -0.103)  | 0.392   |  |
| Indirect effect <sup>3</sup> | -0.017 (-0.100, -0.049)  | 0.548   |  |

Note: We conducted mediation analyses to assess the extent to which MBP-driven IL-17 response explains the inverse association between age and annualized relapse rate (ARR) in people with multiple sclerosis. We compared the group with ≥50 years of age to the group <50 years of age as the reference group. In each mediation analysis, independent variables in the total effect model<sup>1</sup> are age and race/ethnicity. Independent variables in the direct effect model<sup>2</sup> are age, race/ethnicity, and MBP-driven IL-17 level. Indirect effect<sup>3</sup> was calculated by subtracting the direct effect from the total effect. The proportion of the inverse association between age and ARR mediated by MBP-driven IL-17 was 24.6% (-0.037/-0.150) in women and 15.3% (-0.017/-0.111) in men.

Abbreviations: CI = confidence interval

Figure 1. Overall study design.

Figure 2. MBP-driven IL17 response was inversely associated with age in women but not in

men. PBMCs from pwMS were stimulated ex vivo with MBP for 24 hours. IL-17 concentration in the

supernatant was measured using ELISA and plotted against age as a continuous variable (A-C) and

as a binary variable (D-F) using the age threshold of ≥50 years versus <50 years.

Figure 3. MBP-driven IL17 response was inversely associated with relapse rate in women but

not in men. PBMCs from pwMS were stimulated ex vivo with MBP for 24 hours. IL-17 concentrations

were plotted against annualized relapse rate (ARR) within  $\pm 2$  years of sample collection.

Figure 4. Levels of additional MBP-stimulated cytokines and age. PBMCs from pwMS were

stimulated ex vivo with MBP for 24 hours. In an exploratory analysis, concentrations of 57 additional

cytokines in the supernatant were measured using the Luminex xMAP platform human

cytokine/chemokine array. Patient-level Z-score transformed levels of all cytokines are shown (A).

Seven cytokines with marginally significant association with age are highlighted (B). Each row

represents a unique participant in ascending order of age.

Figure 5. Exploratory associations between age and the additional MBP-stimulated cytokines.

The levels of the seven cytokines (from Figure 4B) against age as continuous variable are shown in

scatter plots (left panels) and against age as a binary variable using the age threshold of ≥50 years

versus <50 years are shown in violin plots (right panels).











